IL12RB1 and neoplasm: WTX-330 was developed to include a high-affinity blockade of IL-12/IL-12R engagement systemically via the circulatory system and in nontumor tissues to prolong the half-life of IL-12 for optimal tumor exposure and tumor-selective protease activation through a proprietary mechanism.